Bringing the fundamentals into focus…
Back to Inovio Pharmaceuticals, Inc.
How Inovio Pharmaceuticals, Inc. stacks up
INO · against 194 other Healthcare companies of similar size
Valuation
8/ 100
Near the bottom of its peers.
Ranked #127 of 195 · scores higher than 9% of peers
Bars: peers in each 10-point band of the valuation score69 peers with a valuation score of 0–9, including INO · Click a bar to see the companies
Why valuation scores 8?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -54.5% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -54.2% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -47.1% vs peer median 0.0%
Metric by metric
Position: dot = INO, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | INO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 177 reported | -54.2% | -6.1% | 22% | 30% | |
| EBITDA yieldHigher is better · 203 reported | -54.5% | 1.3% | 16% | 50% | |
| Free cash flow yieldHigher is better · 126 reported | -47.1% | -14.4% | 21% | 20% | |
| Book yieldHigher is better · 184 reported | 3.2% | 65.9% | 9% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around INO| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 834M HKD (≈$107M) | 99 | 57 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 1 | 592M ILS (≈$160M) | 99 | 84 | |
| 127 | 234M USD | 8 | ||
| 127 | 207M USD | 8 | 41 | |
| 127 | 90M USD | 8 | 27 | |
| 127 | 238M USD | 8 | 41 | |
| 127 | 172M USD | 8 | 3 | |
| 127 | 275M USD | 8 | 46 | |
| 127 | 327M USD | 8 | 11 | |
| 127 | 172M USD | 8 | 41 | |
| 127 | 319M USD | 8 | 28 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score